p53 homologue p63 encodes for different isotypes able to either transactivate p53 reporter genes (TAp63) or act as p53-dominant-negatives. p63 is detected in prostatic basal cells in normal prostate; however, it is negative in malignant tumors of the prostate gland. Thus p63 antibody may be a valuable tool in the differential diagnosis of benign and malignant tumors of prostate gland and can be used in a panel of antibodies such as HMW CK [34ßE12], PSA and PSAP. p63 may play a significant role in prostate development by maintaining a prostate stem cell population. Striated muscle staining may be observed with p63.

Intended Use


Species Reactivity

Human, Mouse, Rat


Mouse Monoclonal









Positive Control

Normal prostate

Download Data Sheet
Download intelliPATH™ Data Sheet
Download RUO Data Sheet for International
Download SDS Sheet

Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.

1. Yang A, et al. p63, a p53 homolog at 3q27–29, encodes multiple products with
transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998 Sep;
2. Signoretti S, et al. p63 is a prostate basal cell marker and is required for prostate
development. Am J Pathol. 2000 Dec; 157(6):1769-75.
3. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic
immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies.
Arch Pathol Lab Med. 2008 Sep; 132(9):1388-96.
4. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin
Pathol. 2007 Jan; 60(1):35-42.
5. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung
carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an
immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg
Pathol. 2011 Jan; 35(1):15-25.
6. Tacha D, et al. A six antibody panel for the classification of lung adenocarcinoma
versus squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2012 May; 20
7. Terry J, et al. Optimal immunohistochemical markers for distinguishing lung
adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg
Pathol. 2010 Dec; 34(12):1805-11.
8. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and
cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma,
squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol.
2008 Jan; 36(1):20-5.
9. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in
breast pathology. Am J Surg Pathol. 2004 Aug; 28(8):1076-91.
10. Hicks DG. Immunohistochemistry in the diagnostic evaluation of breast lesions.
Appl Immunohistochem Mol Morph. 2011 Dec; 19(6):501-5.
11. Yeh IT, Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med. 2008 Mar; 132(3):349-58.
12. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
13. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.


There are no reviews yet.

Be the first to review “p63”